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Intravenous or subcutaneous administered antibodies against anti-TNF alpha are 
highly efficacious in the treatment of inflammatory bowel disease (IBD). Intravenous 
administration of Infliximab (IFX) in Crohn’s disease (CD) can induce remission 
and mucosal healing of ulcers. However,  intravenous administration of IFX is 
associated with high costs, systemic immunosuppression, infusion reactions and the 
development of antibodies to IFX (ATI), Therefore we developed an oral formulation 
of IFX and want to examine if oral IFX can induce clinical remission and mucosal 
healing.   
Aim: 
To evaluate the efficacy and safety of orally administered ColoPulse IFX tablets targeted 
to the ileo-colonic region in CD patients.
Study design: 
Multicentre, open label, observational, pilot study. 
Study population: 
Patients with active ileal or ileo-colonic CD.
Intervention: 
Daily administration of ColoPulse IFX tablets instead intravenously administered IFX. 
The total administered oral dose is the same as the intravenous dose.
Primary  study endpoints: 
Efficacy of oral IFX biosimilar CT-P13 in ColoPulse tablets to induce clinical remission 
based on CDAI score of < 150  at wk 18. 








•	 Clinical response: CDAI reduction from baseline of ≥ 100 points 
•	 Endoscopic remission: for patient with Simple Endoscopic Score for Crohn’s 
Disease (SES-CD) (see table 1) of 3 a drop to 0 and for patient with SES-CD > 3 
a drop ≤ 3
•	 Endoscopic response: proportion of subjects with SES-CD decrease from baseline 
of ≥ 50 % at Week 18  but not meeting criteria for endoscopic remission.
•	 Proportion of subjects with CDAI reduction from baseline of ≥ 70 points at Week 18
•	 Number of patients with reduction in prednisolon  dose below 10 mg  or 
budesonide dose below 6 mg or  off steroids at week 18. 
•	 Proportion of subjects with absence of ulcers ≥ 0.5 cm with no segment with any 
ulcerated surface ≥10% at Week 18
•	 Improvement  in faecal calprotectin and C-reactive-protein (CRP) level . 
•	 Non-remitter: Subjects who do not achieves  clinical remission at week 18
•	 Non responder: Subjects who do not achieve  clinical response  at Week 18. 
Other secondary endpoints
•	 IFX trough level at week 8 and 18 
•	 Proportion of patients with development of antibodies to IFX CT-P13 at week 18
•	 Proportion of subjects with absence of ulcers ≥ 0.5 cm with no segment with any 
ulcerated surface ≥ 10% at Week 18
•	 Improvement in Inflammatory Bowel Disease Questionnaire (IBDQ) scores
Table 1. Definitions of Simple Endoscopic Score for Crohn’s Disease (SES-CD)
SES-CD Values
Variable 0 1 2 3
Size of ulcers None Aphthous ulcers 
(0.1 to 0.5 cm)
Large ulcers
(0.5 to 2 cm)
Very large ulcers
(> 2 cm)
Ulcerated surface None < 10% 10-30% > 30%
Affected surface Unaffected 
segment
< 50% 50%-75% > 75%
Presence of narrowings None Single, can be 
passed







Crohn’s Disease (CD) is a chronic inflammatory bowel disease (IBD) that is 
characterised by a transmural inflammation of the gastrointestinal tract, with a 
predilected involvement of the terminal ileum. Although the exact etiology of CD 
remains to be elucidated, a widely accepted hypothesis is that ubiquitous, commensal 
intestinal bacteria trigger an aberrant, overactive, and ongoing mucosal immune 
response that mediates intestinal tissue damage in genetically susceptible individuals. 
Treatment options for CD depend on site of inflammation, disease activity, and 
patient’s response. Treatment is divided in an induction phase in order to stop the 
mucosal inflammation and heal the mucosal lesions and the maintenance phase in 
order to maintain this non-inflammatory state and prevent complications. Tumor 
necrosis factor-alpha (TNF-alpha) is an important cytokine involved in the mucosal 
inflammation since it induces, maintains and amplifies the inflammation through 
several mechanisms, such as the up-regulation of endothelial adhesion molecules and 
the activation and recruitment of immune cells.1-4
Infliximab (IFX), a chimeric mouse-human monoclonal antibody against TNF 
alpha, is efficacious in the treatment of CD not responding to conventional therapy. 
IFX is effective in inducting and maintaining remission and of both luminal and 
fistulising CD5,6 IFX is administered intravenously at doses based on body weight and 
fixed intervals. This gives rise to certain disadvantages. First, patients need to visit the 
hospital for the treatment and the infusion need to be prepared by trained personnel. 
Furthermore, the patient gets punctured and receives the infusion over a period of 
time at which monitoring by trained personnel takes place. 
Moreover, inherently linked to infusion therapy, acute and late-onset infusion 
reactions can occur.7 Additionally, substantial side effects are expected as TNF 
alpha is an endogenous mediator and systemic administration of IFX will cause 
systemic immunosuppression.8-10 Finally, antibody towards IFX (ATI) could develop 
leading to an increase in side effects or loss of response to IFX therapy.11,12 These 
disadvantages have a negative impact on disease burden and health care cost as well 
as patient-friendliness.13 The majority of these disadvantages could be eliminated if 
IFX is administered orally, targeting the inflamed region, and inducing a local, anti-
inflammatory effect.
The ColoPulse technology is a coating technology which consist of a pH-sensitive 
polymer in which a superdisintegrant is incorporated in the coating matrix.14,15 This 
coating was specifically developed to target the ileo-colonic region in humans and is 
characterized by fast and site-specific drug targeting. ColoPulse capsules and tablets 
has been studied in targeting the ileo-colonic region in healthy subjects as well as CD 
patients and food and time of food intake does not affect coating performance.16-20 
Furthermore, we have shown that IFX compounded in ColoPulse tablets is feasible 
and stable.21 The objective of this proof of concept  study is to treat patients with 
active ileo-colonic CD with orally administered ColoPulse IFX tablets instead of 
intravenously administrated IFX. Efficacy and safety will be investigated as well as oral 
IFX pharmacokinetics and the development of ATI formation after oral IFX treatment.







Rationale and Justification of route of administration 
and dosage
As outlined above, orally administered IFX has several advantages over systemically 
administered IFX in view of health costs and burden and patient friendliness. Besides 
these practical and economic considerations, systemically administered IFX can 
induce the development of ATI. The formation of ATI in CD patients is associated with 
infusion reaction, resulting in a two-fold risk of acute infusion reaction whereas they 
have a six-fold risk of developing serious acute infusion reaction.11,12,22-25 Furthermore, 
several studies demonstrated a correlation between IFX drug concentrations, the 
presence of ATI, and clinical outcome. Episodic IFX treatment in patients with CD has 
been associated with a higher rate of ATI as compared with scheduled maintenance 
therapy. Patients on IFX therapy who develop ATI have a threefold higher increased 
risk of loss of response to therapy compared to those who do not develop ATI’s.12,26 
In addition, ATI are associated with an increased clearance of IFX, which necessitates 
more frequent and/or higher dosing of IFX.27 The development of ATI in turn may 
increase health costs and burden and decrease quality of life for loss of response 
generally leads to intensifying the treatment and patient monitoring and an increase 
of disease symptoms, respectively. It is expected that oral IFX therapy does not results 
in substantial systemic exposure and therefore no development of ATI. Studies have 
shown that tissue IFX concentration correlates with a better and sustained response 
in CD28 and that IFX exerts its effect at least partly by local anti-inflammatory 
and immunomodulatory effects in the bowel.29 Additionally, eight open-label, 
uncontrolled pilot clinical trials have shown that the local administration of IFX in 
postoperative recurrent30 symptomatic isolated intestinal lesions,31 fistulising32-34 or 
stricturing35,36 CD is encouraging, ameliorates symptoms, and can be an effective 
treatment option for patients not responding to conventional therapy. For some 
patients, local administered IFX induces complete remission, even after a follow-up 
period of 30-40 months.31-33 Furthermore, no serious adverse events were observed 
during all eight studies. Moreover, in two of these studies patients were included 
that did not respond to systemically administered IFX and showed a clinical response 
to local administration of IFX.32,36 In another study, no ATI were developed during 
6-month follow-up). Table 2 summarizes these eight studies. The administered dose 
in all studies was lower than the conventional doses, which in general ranges from 
5-10 mg/kg every 2 (induction phase) to 8 (maintenance) weeks. However, no 
rational oral dose can be deduced from these studies as the IFX was injected directly 
into the inflamed areas and oral ileo-colonic-targeted IFX is a less direct manner to 
target these areas. Oral treatment eliminates the necessity to administer IFX directly 
with a syringe in the inflamed area during a colonoscopy or perianal  examination. 
It is an easier, less laborious, and patient friendlier manner to locally target the 
inflammation, which can be performed solely by the patient. Furthermore, daily oral 
IFX treatment ensures a continuous exposure of the inflamed ileo-colonic mucosa 
to IFX and presumably eliminates systemic exposure, which may result in fewer 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































regards to the efficacy. Furthermore, no data is available on the stability of IFX in the 
gastrointestinal tract of humans, of which the stability in the terminal ileum and colon 
is of particular importance for this study. However, the intraluminal pH of the terminal 
ileum and colon is generally not detrimental for proteins (pH 6-8).37-40 Finally, oral IFX 
therapy compliance may be challenging for some patients as they need to administer 
IFX daily and a dose can be forgotten, as opposed to infusion therapy. 
There is no published data on the efficacious dose of oral ileo-colonic-targeted 
IFX. The total dose for every participant is therefore calculated in accordance with the 
intravenous dose of IFX divided by the treatment period in days.
Methods/Design 
Primary Objective: 
Primary objective of the study is to investigate the efficacy  oral IFX biosimilar CT-
P13 in ColoPulse tablets to induce clinical remission based on CDAI score of < 150 at 
week 18 in patient with active ileal or ileo-colonic CD. 
Secondary objectives:
•	 Clinical response: CDAI reduction from baseline of ≥ 100 points 
•	 Endoscopic remission: for patient with SES-CD of 3 a drop to 0 and for patient 
with SES-CD > 3 a drop ≤ 3
•	 Endoscopic response: proportion of subjects with SES-CD decrease from 
baseline of ≥ 50 % at Week 18 but not meeting criteria for endoscopic 
remission.
•	 Proportion of subjects with CDAI reduction from baseline of ≥ 70 points at 
Week 18
•	 Number of patients with reduction in prednisolon dose below 10 mg or 
budesonide dose below 6 mg or off steroids at week 18. 
•	 Proportion of subjects with absence of ulcers ≥ 0.5 cm with no segment with 
any ulcerated surface ≥10% at Week 18
•	 Improvement in faecal calprotectin and CRP level . 
•	 IFX trough level at week 8 and 18 
•	 Proportion of patients with development of antibodies to IFX CT-P13 at week 18
•	 Improvement in Inflammatory Bowel Disease Questionnaire (IBDQ) scores 
Non-remitter: Subjects who do not achieves clinical remission at week 18
•	 Non responder: Subjects who do not achieve clinical response at Week 18. 
Study design
This study will be a multicentre, open label, observational, proof of concept pilot 
study. The study will be performed at five sites in the north of the Netherlands 
(UMC Groningen, Isala Zwolle, MST Enschede, MCL Leeuwarden, Martini Hospital 
Groningen). In case of slow inclusion study can be extended to a nationwide ICC 
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study. The study consists of visits over 18 weeks. The total duration of drug treatment 
will be 18 weeks. In total, 12 subjects will receive the study drug. 
Patient population:
Patients with active ileal or ileocolonic Crohn’s disease (CD). The aim is to enroll 
about 12 CD patients with refractory CD. 
Inclusion criteria
•	 Male or female subjects aged 18 to 80 years at screening 
•	 Subject must provide written informed consent prior to any study-related 
procedures, and have the ability to comply with the study procedures
•	 Subject has signs and symptoms consistent with a diagnosis of CD for at least 
3 months (prior to first administration). The diagnosis should be confirmed 
by clinical and endoscopic evidence and supported by histology. CDAI score of 
> 220 and <450 and an average daily stool frequency ≥ 4 points and/or an 
abdominal pain of ≥ 2 points
•	 CRP >5 mg/L or Fecal calprotectin > 200 mg/kg. 
•	 Has one or more ulceration on screening ileocolonoscopy which will result in an 
SES-CD total score of at least 3.  
•	 Non active/non draining fistulas (including seton drained fistulas)
•	 Meets the following requirements for prior or current medications for CD:
a) Has failed conventional therapy:
 i) Is currently receiving corticosteroids and/or immunomodulators (ie,   
  thiopurine, MTX) at adequate therapeutic doses;
OR
ii) Has a history of failure to respond to, or tolerate, an adequate course of   
  corticosteroids and/or immunomodulators (ie, thiopurine, MTX);
OR
iii) Is corticosteroid dependent or has a history of corticosteroid dependency;
AND
b) Has not previously received an approved biologic for CD (ie, IFX, adalimumab,
     certolizumab pegol, ustekinumab, natalizumab, vedolizumab or approved   
          biosimilars of these agents) 
•	 If the subject is taking the following background therapies for CD, a stable dose 
must be maintained before baseline as indicated below:
-  prednisone (doses ≤ 20 mg per day) or equivalent with a stable dose for   
 at least 2 weeks prior to Screening endoscopy.
-  budesonide therapy (doses ≤ 9 mg per day) or beclomethasone doses  
   ≤ 5 mg/day at a stable dose for at least 2 weeks prior to the Screening   
         endoscopy.








•	 Known history of other cause of colitis; e.g. ulcerative colitis, indeterminate 
colitis, microscopic colitis, ischaemic colitis or radiation-induced colitis, 
infectious colitis.
•	 Current abscess 
•	 Symptomatic stricture or stenosis
•	 Subject is likely to require, in the physician’s judgment, bowel resection within 
18 weeks of entry into the study.
•	 Abdominal, enterocutaneous or pelvic active fistulas or fistula likely to require 
surgery during the study. 
•	 History of short bowel syndrome.
•	 Presence of ileostomy or colostomy.
•	 Previous use of anti-TNF alpha therapy.
•	 Prior primary efficacy failure of or secondary loss of response to anti-TNF-alpha 
therapy.
•	 Contra-indication to anti-TNF-alpha therapy.
•	 Positive result of tuberculosis surveillance.
•	 Presence of hepatitis B surface antigen (HBsAg), core antigen (HBcAg) or surface 
antibody (HBsAg), positive hepatitis C.
•	 Subject has documentation of a positive test for toxin producing Clostridium 
difficile (C. difficile), or polymerase chain reaction (PCR) examination of the 
stool on their most recent test, which must have been done in the past 60 days. 
If positive, subjects may be treated and retested no earlier than 7 days after 
completion of treatment.
•	 Subject has a history of active cancer within 5 years, including solid tumors 
and hematological malignancies (except basal cell and in situ squamous cell 
carcinomas of the skin or cervical dysplasia/cancer that have been excised and 
resolved); or colonic dysplasia that has not been completely removed.
•	 Oral antibiotics used for the treatment of Crohn’s disease.
•	 Subject has received a live or live attenuated vaccine within 4 weeks prior to the 
first dose of colopulse IFX
•	 Subject has chronic nonsteroidal anti-inflammatory drug (NSAID) use (note: 
occasional use of NSAIDs and acetaminophen [eg, headache, arthritis, myalgias, 
or menstrual cramps], aspirin up to 325 mg/day is permitted).
Permitted CD medications for the study are:
•	 Prednisone (doses ≤ 20 mg per day) or equivalent with a stable dose for at least 2 
weeks prior to Screening endoscopy.  Corticosteroïds will be tapered by 5 mg per week. 
•	 Budesonide therapy (doses ≤ 9 mg per day) or beclomethasone doses ≤ 5 mg/
day at a stable dose for at least 2 weeks prior to the Screening. Budesonide will 
be tapered by 3 mg per week. 
•	 Subject has discontinued oral or rectal aminosalicylates. 
•	 Methotrexate,thiopurines (ie azathioprine, 6-Mercaptopurine or Thioguanine). 
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Use of medication that can influence gastrointestinal pH, such as gastric antacids 
(calcium carbonate and the like), proton pump inhibitors (omeprazole, pantoprazole, 
and the like), and H2 antihistamine receptor antagonist (ranitidine and the like) are 
not allowed in this study.
Dosages, dosage modifications and method of 
administration
In this study we used CT-P13 IFX (a biosimilar). This biosimilar is proven to be as 
effective as its originator Remicade in vitro and in vivo.41 CT-P13 IFX 5 mg-sugar glass 
tablets coated with the ColoPulse technology are administered. No comparator or 
placebo is used during this study. Treatment consists of an oral daily dose in accordance 
with the intravenously administered dose of IFX, namely 5 mg/kg on day 0 with a 
repeated dose after 2 weeks (induction dose). Subsequently, another dose after 6 
weeks of the first dose is given and thereafter a dose is administered every 8 weeks. 
This dose regimen is converted to a daily oral dosing regimen rounded to multiples 
of 5 mg evenly spread out over time. For example, if a participant of 80 kg were to 
receive one intravenous dose of 80 kg * 5 mg = 400 mg IFX in the first 2 weeks, 
then in this study the participant would receive 400 mg / 14 days = 30 mg oral IFX 
per day. A total daily dose equal to or greater than 10 mg is administered twice daily 
whereas a total daily dose of 5 mg is administered once daily. Table 3 summarizes the 
oral dosing regimen of this study.
Study outline
Table 4 shows the study outline. In brief, the demographic and baseline characteristics 
of interest include age, sex, smoking history, race/ethnicity, disease duration, extend 
and severity, extra intestinal complaints and (prior and concurrent) therapies (and 
results of those, and possible adverse events) for CD. Blood samples for hematology 
and serum chemistry panel and serum will be done in week 0, 2, 6, 14 and 18. 
Hematology sample will be drawn in the standard collection tube that is available at 
each investigational site. Hematology panel consists of: hemoglobin, hematocrit, red 
blood cell count, MCV, MCH, MCHC, WBC, differential, thrombocytes. These samples 
will be obtained in the standard collection tube that is available at each investigational 
site. Blood chemistry panel consists of: blood urea nitrogen (BUN), creatinine, total 
protein, albumin, total bilirubin (and direct bilirubin if total bilirubin is abnormally 
elevated), alkaline phosphatase, amylase, GGT, ALT, AST,  sodium, potassium, and CRP. 
At week 0 blood samples will be taken for DNA research. This is for further research to 
identify and conform HLA regions associated with development of antibodies to IFX 
in IBD patients and to identify novel genetic regions associated with the development 
of ATI.42 At week 0, 2, 6, 14 and 18, the calprotectin level will be measured in the feces 
in the UMCG laboratory. The IFX trough level in sera will be measured at week 2, 6, 
14 and 18 by an ELISA at Sanquin, Amsterdam.43 An colonoscopy will be performed 







at week 0 and week 18 to assess of the severity of the inflammation (week 0) and 
to assess the response (by using the SES-CD score) of the treatment (week 18). At 
week 0, 2, 6, 14 and 18 the CDAI score will be calculated. The quality of life will be 
measured by the IBD-Q questionnaires at week 0 and week 18.
Escape Medication 
Escape medication will be given in this study to patients who do not show response
(CDAI reduction from baseline of ≥ 100 points  at week 18).  Escape medication is IFX 
CT P13 in the normal induction dose and scheme (5 mg/kg, 0-2-6 weeks and every 8 
weeks thereafter). The same study parameters will be studied at week 18 after rescue
medication inclusive the colonoscopy. It is possible that these patients are primary 
non responders and have to switch to another biological or other anti-TNF agents. 
This depends on the presence of antibodies to IFX that are measured in week 18. 
Table 3. The oral IFX dosing regimen of this study.
Day of treatment 0-14 15-28 29-42 43-every 8 weeks
Daily oral dose (5 mg/kg) / 14 (5 mg/kg) / 14 (5 mg/kg) / 14 (5 mg/kg) / 56
Table 4. Study outline. 
Week
Intervention                                                         0 2 6 14 18
Baseline information x
Laboratory diagnostics (Hb, leukocytes, 
thrombocytes, CRP, albumin, AST, ALT, AF, 
GammaGT, bilirubin, urea, creatinin)
x x x x x
Blood for DNA analysis x
Faeces calprotectin x x x x x
Endoscopy x x
CDAI/HBI x x x x x
S IBD Q x x
IFX level x x 
Antibodies to IFX x
Adverse events x x x x x
Collect stool x x x x





This is an open label proof of principle study. No formal statistical hypothesis testing 
will be performed for this study. Descriptive statistics and 95% confidence intervals 
will be employed where appropriate for data analysis. The sample size for this study 
was determined to account for the variability within the heterogeneous group of CD 
and is not based on statistical power calculation. In the first IFX placebo controlled 
trial with 5 mg/kg IFX clinical response and clinical remission at 12 weeks was 48 
% and 30 % and the placebo response and remission 12 % and 8 % respectively.44 In 
the phase 3 SONIC trial, which compares IFX 5 mg/kg monotherapy to combination 
therapy with Azathioprine, remission rates defined as CDAI <150-points, clinical 
response defined as  >100-point decrease  in CDAI from baseline  and clinical response 
defined as >70-point decrease  in CDAI from baseline in the IFX monotherapy arm 
at Week 18 were 49,7%, 55% and 60,9% respectively. IBDQ and CRP change from 
baseline at week 18  were 39,9 and -1,3 (mean ± SD) respectively.45 The percentage 
responders at 18 weeks is expected to be 20% higher than the placebo response 
rate of 12 % and placebo remission rate of 8%. A fully sequential design with 
continuous monitoring of response will be used. A total of 39 patient is needed to 
show efficacy. The efficacy is scored according to clinical response (CDAI reduction 
from baseline of ≥ 100 points and of ≥ 70 points) and clinical remission efficacy 
criteria. In case one or more of these efficacy criteria is achieved this will be called 
an “event”, and these events will be plotted in a diagram (Figure 1). In case the event 

















The between-group difference in the primary outcome will be analyzed using the Chi 
square test of Fisher exact test when appropriate. 
Secondary endpoint
With regard to the secondary endpoints reflecting ‘time to event’.  We will compute 
survival curves (time-to-event analysis) for both groups using the Kaplan-Meier 
methodology. Significance of differences between curves will be calculated using the 
log-rank test.
The remaining secondary outcomes will be analyzed using the appropriate parametric 
or non-parametric techniques (two group t-test, Mann-Whitney U test, Chi-square 
test or Fisher exact test).
Safety monitoring and ethics
This research will be conducted according to the principles of the Declaration of 
Helsinki Fortaleza (Brasil) in 2013 in accordance with the Medical Research Involving 
Human Subjects Act (WMO) (Wet Medisch Wetenschappelijk onderzoek met 
mensen).  Written informed consent will be obtained from patients before inclusion 
in the trial.
All adverse events (AE), whether or not considered related to the oral IFX, will 
be registered. Moreover, serious adverse events (SAEs) and suspected unexpected 
serious adverse reactions (SUSARs) will be reported to the accredited Medical Ethical 
Committee (MEC). 
The risk of this study is considered ‘low’ because of IFX is an common used drug. 
An independent data and safety monitoring board (DSMB) will examine safety 
parameters and evaluate the overall progress of the trial. The DSMB will consist of 
an epidemiologist/statistician who is the chairman, an independent surgeon and an 
independent internist. The responsibilities of the DSMB are to monitor safety data 
when 50% of the patients have been randomized and, if required, on ad hoc basis. 
Any mortality will be reported directly to the DSMB and evaluated for cause of death 
and possible trial related serious adverse events. 
The justifications for a recommendation to terminate the study due to clear harm 
will be based on a notably increase of (serious) adverse events. Statistical stopping 
boundaries will not be pre-specified. 
The advice(s) of the DSMB will only be sent to the principal investigator of the 
study. Should the principal investigator decide not to fully implement the advice of the 
DSMB, the principal investigator will send the advice to the reviewing MEC; including 




IFX has been proven to be effective in the treatment of CD and is effective in induction 
and maintaining remission of CD.5,46 It is administered intravenously at doses based 
on weight and fixed intervals. Previous studies showed that local treatment with 
IFX is efficacious like topic IFX injection for rectal stenosis in CD patients.47 Also in 
other studies where local IFX was administered is was proven to be effective (table 
2).30-36 Additionally, topical IFX treatment presumably results in a continuous IFX 
exposure at the site of inflammation with fewer side effects compared to systemically 
administered IFX.  The development of a subcutaneous formulation of CT-P13 IFX 
for rheumatoid arthritis is described.48 These patients had more stable steady state 
therapeutic blood levels of IFX and have lower rate of ATI compared with patients 
receiving continued IFX IV treatment. More recently in IBD patients also efforts 
has been made to use subcutaneous IFX. Preliminary results suggest that one year 
treatment with subcutaneous CT-P13 IFX is similar in efficacy and safety compared 
to intravenous administration in CD patients.49 There are gut specific oral agents 
in treatment of IBD like slow release mesalazine and budesonide. These drugs are 
proven to be effective in IBD. Beside these there are local acting drugs like mesalazine 
suppositories, mesalazine enemas and beclometason/budesonide suppositories and 
enemas. Several oral targeted therapies are in development.50 Efficacious oral anti-
TNF alpha or IFX treatment has major advantages for patients with CD. First, patients 
no longer need to visit the hospital for medical treatment. Second, patients will not 
be punctured by for infusion therapy and also the personnel do not have to receive 
a training for the procedure. Third, oral treatment eliminates infusion quality of life 
influencing related complications, such as extravasations and infusion reactions. 
Finally, local treatment of anti-TNF-alpha reduces the risk of developing of antibodies 
to the anti-TNF-alpha containing agent. An oral administration of the non-absorbable 
recombinant anti-TNF-alpha fusion protein, PRX-106  has been shown to be  safe, not 
associated with immune suppression, while inducing a favorable anti-inflammatory 
immune modulation in healthy volunteers.51 A novel polyclonal anti alpha antibody 
(AVX470) was effective in treating mouse models of colitis, delivering the anti-
TNF to the site of inflammation with minimal systemic exposure.52 Another novel 
anti-TNF alpha domain antibody (V565) could be detected by ELISA in post-dose 
serum of colitis mice, but not in naïve mice, demonstrating penetration of disrupted 
epithelium.53 An open label study in ulcerative colitis demonstrated binding to CD14 
+macrophages in the lamina propria of UC patients and resulted in inhibition of 
mucosal inflammatory processes after 6–7 days oral dosing.54 The colopulse capsule 
is specifically developed to target the ileo-colonic region. This local administration is 
therefore ideal for CD patients with active disease of the terminal ileum. The clinical 
response and endoscopic response are both important at week 18. Of interest, The 
Mongerson trial which showed that patients with CD who received oral Mongersen 
targeting SMAD7, an inhibitor of cytokine transforming growth factors β1 (TGF- 
β1), had significantly higher rate of remission and clinical response than those who 
received placebo.55 However, in a follow-up phase III study the trial was ended due 







to futility. Some important limitations of the phase II trial were addressed in the 
accompanying editorial.56 Namely, the inclusion criteria of the phase II study did 
not include objective criteria for active disease such as endoscopic confirmation 
of inflammation, but were only based on CDAI score. It is therefore unclear what 
proportion of these patients had mucosal lesions.56 Additionally, 40% of the patients 
did not have an increased level of CRP at baseline or had a normalization of CRP 
during the study period. Therefore the clinical remission  and biological remission 
were not in correspondence, a conclusion supporting the later futility of the phase 
III trial. To overcome this problem our protocol has the advantage that IFX has been 
used for many years in CD patients and therefore has proven efficacy and safety 
profile. Additionally, our protocol includes monitoring of disease activity by CDAI 
score (for clinical response) as well as objective measurements such as CRP, fecal 
calprotectin and endoscopic response at week 18. This allows us to combine clinical 
and endoscopic response as a valid primary outcome for CD patients. In conclusion, 
there is a rationale for a trial with  topical IFX delivered with the colopulse technology. 
If proven efficacious, oral IFX therapy could lead to a more patient tailored therapy of 
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